Thornburg Investment Management Inc. Sells 278,291 Shares of Novo Nordisk A/S $NVO

Thornburg Investment Management Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 33.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 544,386 shares of the company’s stock after selling 278,291 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $30,208,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. True Wealth Design LLC raised its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the period. NewSquare Capital LLC boosted its holdings in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $30,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $39,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Six research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Trading Down 1.2%

Shares of NVO opened at $38.13 on Thursday. The firm has a market capitalization of $170.24 billion, a price-to-earnings ratio of 10.99 and a beta of 0.67. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a 1-year low of $37.65 and a 1-year high of $91.90. The company has a 50-day moving average of $53.16 and a 200 day moving average of $53.04.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Seeking Alpha publishes a bullish valuation case and a rating upgrade, arguing the sell‑off creates a deep-value buying opportunity given Novo’s fundamentals and long-term franchise. Novo Nordisk: Can’t Ignore It At These Valuations (Rating Upgrade)
• Positive Sentiment: Novo Nordisk struck a partnership with Vivtex to develop next‑generation oral obesity and diabetes medicines in a deal worth up to $2.1B — a strategic move that strengthens its oral drug-delivery pipeline and could offset injectable franchise pressure over time. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: JPMorgan reaffirmed a Neutral rating on NVO, signaling no change in stance from a large bank and contributing to mixed sell‑side signals rather than decisive bullish momentum. JPMorgan Chase & Co. Reaffirms Neutral Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Short interest fell ~14.9% in February (days-to-cover ~0.9), which reduces one source of downward pressure but doesn’t eliminate the fundamental concerns driving the selloff.
• Negative Sentiment: Multiple analyst downgrades (Kepler, Deutsche Bank and others) and sharply reduced price targets have pressured the stock after late-stage trial news and pricing moves. Kepler cut its rating, citing the changed competitive/pipeline outlook. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: A high-profile late‑stage trial (CagriSema) failed to match Eli Lilly’s Zepbound in a head‑to‑head readout, triggering analyst downgrades and concern about Novo’s next‑generation obesity thesis. That trial miss is a primary catalyst for near‑term weakness. Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
• Negative Sentiment: Novo announced U.S. list price cuts of up to ~50% for Wegovy and large cuts for Ozempic starting in 2027 to improve insured-patient access — a move that helps volume/affordability but is likely to pressure near‑term revenue and margin expectations. Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S.
• Negative Sentiment: A Schall Law Firm shareholder investigation was announced, probing whether the company made misleading disclosures — a legal overhang that raises investor risk until clarified. NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.